BackHomology Medicines Overview

Homology Medicines Total Current Liabilities

Homology Medicines's total current liabilities is $5.4M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$5.40M
↓ 53.17% YoYΔ $-6.13M vs prior year quarter

Peer trimmed avg / median

Loading

Homology Medicines Total Current Liabilities History

Loading

Homology Medicines vs. peers: Total Current Liabilities Comparison

Loading

Homology Medicines Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Homology Medicines (FIXX) FAQ

As of the most recent data (June 2026), FIXX shows a total current liabilities of $5.4M. That compares with $12M in the prior-year period — down 53.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, FIXX's total current liabilities is now $5.4M (was $12M) — a 53.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Homology Medicines is outperforming or lagging.

Tracking FIXX's total current liabilities over time shows whether Homology Medicines is scaling, shrinking, or reshaping that part of the business. The current reading is $5.4M That compares with $12M in the prior-year period — down 53.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has Homology Medicines's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $5.4M) with ownership activity and broader fundamentals.

Homology Medicines's total current liabilities is $5.4M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.